Skinvisible announces 99.6% transdermal penetration of GLP-1 drug in preclinical study

SKINVISIBLE, INC.

GLP-1 drug danuglipron formulated with Invisicare showed 99.6% penetration over 6 hours in Franz cell diffusion studies.
CB-1 antagonist formulated with Invisicare showed 62% penetration over 6 hours; sustained delivery with no initial spike.
Company is developing other GLP-1 agonists and CB-1 antagonists for transdermal obesity treatment.
Seeking strategic partnerships to bring first transdermal obesity therapies to market.
Obesity drug market projected to reach $105B-$144B by 2030 per Morgan Stanley.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.